10-Q: AnaptysBio Q3 2025: Revenue Surges, Separation Plans Advance

AnaptysBio reported a significant increase in collaboration revenue for Q3 2025, driven by Jemperli sales milestones, while advancing plans to separate into two independent public companies by year-end 2026.

Summary

• Collaboration revenue for the three months ended September 30, 2025, increased to $76.320 million from $30.017 million in the prior year period.
• Collaboration revenue for the nine months ended September 30, 2025, increased to $126.354 million from $48.167 million in the prior year period.
• Net income for the three months ended September 30, 2025, was $15.113 million, compared to a net loss of $32.851 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $62.846 million, an improvement from a net loss of $123.447 million for the same period in 2024.
• Basic net income per common share was $0.54 for Q3 2025, compared to a loss of $1.14 for Q3 2024.
• Research and development expenses decreased to $31.407 million for Q3 2025 from $42.212 million for Q3 2024.
• The Board of Directors approved plans to explore separating the business into two independent, publicly traded companies by year-end 2026.
• A $50.0 million sales milestone was recognized in Q3 2025 when Jemperli annual sales exceeded $750 million.
• Cash, cash equivalents, and investments totaled $256.7 million as of September 30, 2025.
• Management believes existing cash, cash equivalents, and investments will fund operations for at least the next 12 months.

Sentiment

Score: 7

Explanation: The company reported strong quarterly financial performance, driven by a substantial Jemperli milestone, and showed significant progress in its clinical pipeline with positive data for rosnilimab and ANB033. The strategic plan to separate into two companies could unlock shareholder value. However, the company still has a large accumulated deficit, increased non-cash interest expense, and faces typical biotech development and commercialization risks, including the recent termination of a GSK program.

Positives

• Collaboration revenue for the three months ended September 30, 2025, increased by over 150% to $76.320 million, primarily driven by a $50.0 million Jemperli sales milestone.
• Achieved net income of $15.113 million for the three months ended September 30, 2025, a substantial improvement from a net loss of $32.851 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, was nearly halved to $62.846 million from $123.447 million in the prior year period.
• Research and Development expenses decreased by $10.8 million for the three months ended September 30, 2025, and $10.9 million for the nine months ended September 30, 2025.
• Rosnilimab Phase 2b trial for moderate-to-severe rheumatoid arthritis achieved its primary endpoint (mean change from baseline in DAS-28 CRP score) and ACR20 response at Week 12 for all three doses.
• Rosnilimab demonstrated clinically meaningful efficacy with deepening of responses through six months on CDAI LDA, CDAI remission, and ACR70 in RA patients, independent of prior treatments.
• Translational data for rosnilimab showed robust, on-target pharmacological activity, including approximately 90% reduction in pathogenic T cells in blood and synovial biopsies.
• Rosnilimab showed a favorable safety and tolerability profile across all doses with no treatment-related serious adverse events, malignancies, anaphylaxis, or systemic hypersensitivity.
• ANB033 Phase 1a trial in healthy volunteers showed favorable PK profile, full receptor occupancy, and potent effect with 70-75% reduction in CD122-expressing CD8 T cells and elimination of CD122-expressing NK cells, without meaningful reduction in overall CD8 T cells or regulatory T cell counts.
• Jemperli (out-licensed to GSK) received multiple FDA and EMA approvals for endometrial cancer, including in combination with chemotherapy, demonstrating strong regulatory success.
• Management believes existing cash, cash equivalents, and investments ($256.7 million as of September 30, 2025) will fund operations for at least the next 12 months.

Negatives

• Cash and cash equivalents decreased to $109.833 million as of September 30, 2025, from $123.080 million as of December 31, 2024.
• Total assets decreased to $353.098 million as of September 30, 2025, from $483.834 million as of December 31, 2024.
• Accumulated deficit increased to $822.173 million as of September 30, 2025, from $759.327 million as of December 31, 2024.
• Stockholders (deficit) equity turned negative, from $70.868 million as of December 31, 2024, to $(29.416) million as of September 30, 2025.
• Non-cash interest expense for the sale of future royalties significantly increased to $22.515 million for Q3 2025 from $15.413 million for Q3 2024, and to $60.182 million for the nine months ended September 30, 2025, from $32.683 million for the same period in 2024, primarily due to the Jemperli Amendment.
• Interest income decreased due to lower investment balances and timing of sales/maturities.
• Net cash used in operating activities increased to $78.300 million for the nine months ended September 30, 2025, from $68.665 million for the same period in 2024.
• Net cash used in financing activities was $89.479 million for the nine months ended September 30, 2025, compared to net cash provided of $99.487 million for the same period in 2024, largely due to common stock repurchases.
• GSK terminated the TIM-3 antagonist antibody development program in October 2025, meaning no future milestones or royalties from this program.
• The proposed separation of the business is anticipated to be a taxable event.
• The proposed separation is subject to various risks and uncertainties and may not achieve all anticipated benefits, potentially leading to increased costs and management distraction.

Risks

• Product candidates in development may fail or suffer delays, adversely affecting their commercial viability, and initial clinical trial results may not predict later-stage outcomes.
• Ongoing and planned clinical trials may reveal significant adverse events, toxicities, or other side effects, which could inhibit regulatory approval or market acceptance.
• Inability to obtain, or delays in obtaining, required regulatory approvals in the United States or foreign jurisdictions would materially impair the ability to commercialize and generate revenue.
• Even if product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and surveillance.
• The company may not be successful in expanding its pipeline of product candidates and developing marketable products due to limited resources and focus.
• Lack of history in commercializing biotechnology products makes it difficult to evaluate the prospects for future viability and successful transition to a commercial-stage company.
• Significant competition from more effective, safer, or less expensive products developed and marketed by competitors could negatively impact commercial opportunities.
• Product candidates may not achieve adequate market acceptance among physicians, patients, health care payors, and others in the medical community necessary for commercial success.
• The company currently has no marketing and sales force and may be unable to establish effective capabilities or enter into agreements with third parties to sell or market product candidates.
• The manufacture of biologics is complex, and third-party manufacturers may encounter difficulties in production, leading to delays or cessation of supply for clinical trials or commercialization.
• Political, economic, or public health events may have a material impact on the U.S. and global economies and could adversely impact the business, financial condition, and results of operations.
• The company has limited operating revenue and a history of operational losses, with no guarantee of achieving or sustaining profitability.
• Additional capital will be required to finance operations, which may not be available on acceptable terms, or at all, potentially preventing the completion of development and commercialization.
• The proposed separation of the business into two independent, publicly traded companies is subject to various risks and uncertainties and may not be completed on the terms or timeline currently contemplated, if at all, and will involve significant time, effort, and expense.
• Dependence on existing collaborations (e.g., GSK) and potential future collaborations; inability to maintain or success of these collaborations could adversely affect the business.
• Inability to obtain or protect intellectual property rights in the U.S. and throughout the world could prevent effective competition.
• Difficulty attracting and retaining highly skilled employees is crucial for success.
• The market price of the company's stock has been and may continue to be volatile, leading to potential investment losses.
• Broad discretion in the use of net proceeds from public offerings may not lead to effective allocation that increases stockholder value.
• The company may be subject to securities litigation, which is expensive and could divert management attention.
• Requirements of being a public company may strain resources, divert management attention, and affect the ability to attract and retain executive management and qualified board members.
• Future sales and issuances of common stock or rights to purchase common stock, including pursuant to equity incentive plans, could result in additional dilution.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• The company does not intend to pay dividends on its common stock, limiting returns to stock value appreciation.
• Cash and investments could be adversely affected if the financial institutions in which they are held fail.
• Provisions in organizational documents and Delaware law might discourage, delay, or prevent a change in control of the company or changes in management.
• Exclusive forum provisions in organizational documents may limit stockholders' ability to bring claims in a preferred judicial forum.
• Dependence on a small number of suppliers for raw materials necessary to produce product candidates could lead to supply disruptions.
• Ability to use federal and state net operating loss (NOL) carryforwards to offset taxable income in future years could be limited by ownership changes or state-level suspensions.

Future Outlook

AnaptysBio anticipates reporting top-line Phase 2 data for rosnilimab in ulcerative colitis in November or December 2025. The company plans to initiate an additional Phase 1b trial for ANB033 in a second inflammatory disease in 2026 and expects to report top-line Phase 1b data from the celiac disease trial for ANB033 by the fourth quarter of 2026. The proposed separation of the business into two independent, publicly traded companies is expected to be completed by year-end 2026, with the biotechnology company launching with adequate capital for at least two years of operations. General and administrative expenses and research and development expenses are expected to increase for the foreseeable future as product candidates advance and public company costs are incurred. Management believes existing financial resources will fund operations for at least the next 12 months.

Management Comments

• Our management believes our currently available resources will provide sufficient funds to enable us to meet our operating plans for at least the next 12 months from the issuance of our consolidated financial statements.
• While the separation is anticipated to be a taxable event, we are focused on minimizing overall corporate and shareholder-level taxes across the entire transaction.
• We expect that our general and administrative expenses will increase for the foreseeable future as we incur costs associated with being a publicly traded company, including stock compensation expense, legal, auditing and filing fees, additional insurance premiums, investor relations expenses and general compliance and consulting expenses.
• We expect our research and development expenses to be higher for the foreseeable future as we continue to advance our product candidates.

Industry Context

AnaptysBio operates in the highly competitive clinical-stage biotechnology industry, focusing on immunology therapeutics for autoimmune and inflammatory diseases. The company's pipeline, including rosnilimab, ANB033, and ANB101, targets significant market opportunities in areas like rheumatoid arthritis, ulcerative colitis, and celiac disease. The strategy of out-licensing assets like Jemperli to GSK and imsidolimab to Vanda Pharmaceuticals is a common approach for smaller biotech firms to generate revenue and fund internal pipeline development. The proposed separation into a royalty management company and a clinical-stage biotech company reflects a trend towards optimizing value for distinct asset classes within a single entity, potentially appealing to different investor profiles. The termination of the TIM-3 antagonist program by GSK highlights the inherent risks and evolving priorities in pharmaceutical collaborations.

Comparison to Industry Standards

• Rosnilimab (RA): Competitors include monoclonal antibodies targeting anti-TNF (Humira; Abbvie), IL-6 (Actemra; Roche and Kevzara; Regeneron), CD-80/86 (Orencia; BMS), CD-20 (Rituxan; Roche), and janus kinase inhibitors (Rinvoq; AbbVie, Olumiant; Eli Lilly, and Xeljanz; Pfizer). Non-depleting PD-1 agonist antibodies like GS-0151 (Gilead) and a Seismic PD-1 agonist are in earlier Phase 1/1b development. Rosnilimab's positive Phase 2b data and favorable safety profile suggest a competitive entry, especially with potential for extended dosing.
• Rosnilimab (UC): Commercial-stage competitors include anti-TNF (Humira; Abbvie and Remicade; Johnson & Johnson), anti-α4β7 (Entyvio; Takeda), anti-IL-23 (Stelara; Johnson & Johnson, Omvoh; Eli Lilly, Tremfya; Johnson & Johnson, and Skyrizi; AbbVie), S1P inhibitors (Zeposia; Bristol Myers Squibb and Velsipity; Pfizer), and janus kinase inhibitors (Rinvoq; AbbVie, and Xeljanz; Pfizer). Anti-TL1A antibodies (PRA023; Merck, RVT-3101; Roche and duvakitug; Teva/Sanofi) are in Phase 2 and 3, and a miR-124 enhancer (Abivax) is in Phase 3. Rosnilimab is in Phase 2, indicating it is earlier in development compared to many established and late-stage competitors.
• ANB033 (anti-CD122 antagonist): Clinical competitors include FB-102 (Forte Bioscience) in Phase 2a for CeD and vitiligo, and anti-IL-15 monoclonal antibodies like GIA-632 (Novartis) in Phase 2a for atopic dermatitis and Phase 1b for CeD and EoE, and TEV-408 (Teva) in Phase 2 for CeD and vitiligo. ANB033's positive Phase 1a data with potent CD122-expressing T and NK cell reduction without broad immune suppression positions it favorably in early development.
• ANB101 (anti-BDCA2 program): Competitors include litifilimab (Biogen) in Phase 3 development for SLE and CLE, and daxdilimab (Amgen) in Phase 2 development for dermatomyositis or anti-synthetase inflammatory myositis, and discoid lupus erythematosus. ANB101 is in Phase 1, indicating it is significantly earlier in development than some competitors in related indications.
• Jemperli (PD-1 antagonist): Multiple FDA and EMA approvals for endometrial cancer, including in combination with chemotherapy, demonstrate strong regulatory success and market penetration for this out-licensed asset, contributing significant non-cash royalty and milestone revenue.

Corporate Governance

Legal Proceedings

• Not currently a party to any litigation or legal proceedings that, in the opinion of management, are probable to have a material adverse effect on the business.

Stakeholder Impact

• Shareholders: Potential for increased value through the proposed separation into two companies, but also dilution risk from future capital raises and stock repurchases. Positive clinical data could boost share price, while operational losses and increased non-cash interest expense are headwinds.
• Employees: Continued focus on research and development, potential for new opportunities within the two separate entities post-separation. Stock-based compensation remains a significant part of overall compensation.
• Customers (Collaborators like GSK, Vanda): Continued collaboration on Jemperli and imsidolimab, but GSK terminated the TIM-3 program, indicating evolving partnership dynamics.
• Patients: Progress in clinical trials for rosnilimab (RA, UC), ANB033 (CeD), and ANB101 offers potential new therapeutic options for autoimmune and inflammatory diseases.
• Creditors (Royalty Monetization Holders): Sagard and DRI continue to receive royalty and milestone payments as per agreements, with increased non-cash interest expense reflecting the terms of these agreements.

Next Steps

• Report top-line Phase 2 data through Week 12 for rosnilimab in ulcerative colitis in November or December 2025.
• Initiate an additional Phase 1b trial for ANB033 in a second inflammatory disease in 2026.
• Report top-line Phase 1b data from the celiac disease trial for ANB033 by the fourth quarter of 2026.
• Complete the proposed separation of the business into two independent, publicly traded companies by year-end 2026.
• Launch the biotechnology company (Biopharma Co) with adequate capital to fund operations for at least two years post-separation.
• Seek additional financing and/or strategic investments as needed for expansion.
• Continue to advance rosnilimab, ANB033, and ANB101 through clinical development.
• Re-evaluate the variable transaction price for royalty monetization agreements at each reporting period.

Key Dates

Recommendation

The company demonstrated strong quarterly financial performance driven by a significant Jemperli milestone and reported positive clinical data for rosnilimab and ANB033, which are encouraging for its pipeline. The strategic plan to separate into two independent companies could unlock value by allowing investors to choose exposure to either the royalty stream or the clinical-stage biotech assets. However, the company still faces substantial operational losses year-to-date, a negative stockholders' equity, and increased non-cash interest expense from royalty monetization. The inherent risks of clinical development, competition, and the complexities of the proposed separation warrant a cautious approach. A 'hold' recommendation allows investors to observe the execution of the separation plan and further clinical trial readouts before making a more definitive investment decision.

Keywords

Biotechnology, Immunology, Autoimmune diseases, Inflammatory diseases, Rosnilimab, ANB033, ANB101, Jemperli, Dostarlimab, Imsidolimab, Rheumatoid arthritis, Ulcerative colitis, Celiac disease, BDCA2 modulator, Clinical-stage, SEC filing, 10-Q, Biopharma, Royalty monetization, Drug development, Clinical trials, GSK, Vanda Pharmaceuticals